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Abstract
Background: Previous studies have shown beneficial effects of levosimendan in high-risk patients undergoing
cardiac surgery. Two large randomized controlled trials (RCTs), however, showed no advantages of levosimendan.
Methods: We performed a systematic review and meta-analysis (MEDLINE and Embase from inception until March 30,
2017), investigating whether levosimendan offers advantages compared with placebo in high-risk cardiac surgery
patients, as defined by preoperative left ventricular ejection fraction (LVEF)≤ 35% and/or low cardiac output syndrome
(LCOS). The primary outcomes were mortality at longest follow-up and need for postoperative renal replacement
therapy (RRT). Secondary postoperative outcomes investigated included myocardial injury, supraventricular arrhythmias,
development of LCOS, acute kidney injury (AKI), duration of mechanical ventilation, intensive care unit and hospital
lengths of stay, and incidence of hypotension during drug infusion.
Results: Six RCTs were included in the meta-analysis, five of which investigated only patients with LVEF≤ 35% and one
of which included predominantly patients with LCOS. Mortality was similar overall (OR 0.64 [0.37, 1.11], p = 0.11) but lower
in the subgroup with LVEF < 35% (OR 0.51 [0.32, 0.82], p = 0.005). Need for RRT was reduced by levosimendan both overall
(OR 0.63 [0.42, 0.94], p= 0.02) and in patients with LVEF < 35% (OR 0.55 [0.31, 0.97], p= 0.04). Among secondary outcomes,
we found lower postoperative LCOS in patients with LVEF < 35% receiving levosimendan (OR 0.49 [0.27, 0.89], p= 0.02),
lower overall AKI (OR 0.62 [0.42, 0.92], p= 0.02), and a trend toward lower mechanical support, both overall (p= 0.07) and
in patients with LVEF < 35% (p= 0.05).
Conclusions: Levosimendan reduces mortality in patients with preoperative severely reduced LVEF but does not affect
overall mortality. Levosimendan reduces the need for RRT after high-risk cardiac surgery.
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Background
Over the last two decades, the risk profile of patients
undergoing cardiac surgery has increased significantly
[1, 2], and currently more than 1 million cardiac surgery
procedures are performed annually in the United States
and Europe [3]. Older patients and those with a higher
degree of comorbidities are currently referred for cardiac
surgery [4], and, even if such patients may benefit from
cardiac surgery, they are at increased risk for periopera-
tive complications that result in high morbidity and
mortality [5]. Patients with a severely depressed left
ventricular ejection fraction (LVEF < 35%) are particu-
larly at increased risk of developing postoperative low
cardiac output syndrome (LCOS) [6], which in turn is
associated with higher mortality [7].
Levosimendan, a calcium-sensitizing inotrope and an
ATP-sensitive potassium channel (KATP) opener, has
been investigated as a pharmacological strategy to de-
crease mortality in cardiac surgery [8–10]. The intraop-
erative and postoperative use of levosimendan is mainly
a rescue strategy for patients with difficult weaning from
cardiopulmonary bypass (CPB) or in cases of LCOS.
One recent meta-analysis showed that levosimendan
seems to be the most effective drug in decreasing mor-
tality after cardiac surgery [11], and another showed that
the reduction in mortality and postoperative complica-
tions is driven by studies where levosimendan was used
in patients with low LVEF [12].
Two randomized controlled trials (RCTs) published at
the beginning of 2017 have not shown beneficial effects
of the use of levosimendan compared with placebo in
patients with preoperative severely depressed LVEF [13]
or in a mixed population of patients with either pre-
operative severely depressed LVEF or profound intra-/
postoperative cardiovascular dysfunction [14]. Nonethe-
less, researchers in the first study reported a beneficial
effect in a subgroup of patients with a more severe
reduction of LVEF [13]. Therefore, we aimed to conduct
a new meta-analysis in light of the recently published
RCTs, specifically examining the efficacy of levosimen-
dan compared with placebo in decreasing mortality and
need for renal replacement therapy (RRT) in high-risk
cardiac surgery.
Methods
Eligibility criteria
We conducted a systematic search and meta-analysis of
RCTs comparing levosimendan with placebo in high-risk
patients undergoing cardiac surgery. We defined three
subgroups of high-risk patients: (1) those with a pre-
operative severely depressed LVEF (<35%, the low LVEF
subgroup), (2) patients with intra- and/or postoperative
cardiovascular dysfunction requiring high pharmaco-
logical and/or mechanical support (LCOS subgroup),
and (3) a mixed population of the previous two groups
(low LVEF and LCOS subgroup). We excluded studies
comparing levosimendan with other pharmacological
strategies such as dobutamine and milrinone.
Search strategy and criteria
Using the NHS Library Evidence tool, we undertook a
systematic web-based advanced literature search of
studies evaluating the use of levosimendan in high-risk
cardiac surgery. We followed the approach suggested by
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement for reporting system-
atic reviews and meta-analyses [15], and a PRISMA
checklist is provided separately (Additional file 1). A com-
puterized search of the MEDLINE (PubMed) and Embase
databases was conducted from inception until March 30,
2017, to identify relevant articles. Our core search
combined a group of findings containing the term “levosi-
mendan” with a second group including the words
“cardiac surgery” or “coronary artery bypass grafting” or
“CABG.” Inclusion criteria were prespecified according to
the PICOS (population, intervention, comparison, out-
comes, and study design) approach (Table 1).
We excluded prospective and retrospective studies,
case series, experimental animal studies, book chapters,
reviews, editorials, and letters to the editor. Study selec-
tion for determining eligibility for inclusion in the sys-
tematic review and data extraction was performed
independently by four reviewers (FS, JBK, CS, AA).
Discordances were resolved by involving other authors.
Language restrictions were applied, and only manu-
scripts published in English, French, Spanish, German,
or Italian were included. A manual search was
Table 1 PICOS approach for selecting clinical studies in the
systematic search
PICOS Criteria
1. Participants High-risk patients undergoing cardiac surgery,
defined by preoperative severely depressed
LVEF (<35%) and/or intra-/postoperative LCOS
2. Intervention Levosimendan
3. Comparison Placebo
4. Outcomes Primary outcomes: mortality at longest follow-
up, need for RRT Secondary outcomes:
myocardial injury, supraventricular arrhythmias,
acute kidney injury (risk, injury, or failure according
to RIFLE criteria), duration of mechanical ventilation,
development of LCOS (only for studies on
preoperative severely depressed LVEF patients),
intensive care unit and hospital lengths of stay,
adverse events, or hypotension during drug infusion
5. Study design Randomized controlled trials
Abbreviations: LVEF Left ventricular ejection fraction, LCOS Low cardiac output
syndrome, RIFLE Risk, injury, failure; loss, end-stage renal disease, RRT Renal
replacement therapy, PICOS Population, intervention, comparison, outcomes,
and study design
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conducted independently by three authors (FS, JBK, CS)
to explore the reference lists for the findings of the sys-
tematic search.
Quality assessment
Methodological quality of included RCTs was evaluated
using the Cochrane Collaboration tool, which incorpo-
rates the following domains: selection, performance,
detection, attrition, reporting, and other potential
sources of bias [16].
Groups and endpoints
We primarily compared the efficacy of levosimendan
with placebo with regard to survival at longest follow-up
reported and the need for RRT. A subgroup analysis was
performed according to the three types of high-risk pop-
ulations included in the selected studies (see “Eligibility
criteria” section above), and only when at least three
studies were available in any of the subgroups. The
following secondary endpoints were evaluated: the presence
of myocardial injury; the incidence of atrial fibrillation (AF)
and supraventricular arrhythmias; the occurrence of acute
kidney injury (AKI) risk, injury, or failure (according to the
RIFLE [risk, injury, failure; loss, end-stage renal disease] cri-
teria); the duration of mechanical ventilation (MV); the in-
tensive care unit (ICU) and hospital lengths of stay (LOS);
the incidence of any adverse events; and the incidence of
hypotension during drug infusion. Moreover, for the sub-
group of studies including only patients with preoperative
severely reduced LVEF, we evaluated the development of
intra- and postoperative LCOS.
Two types of sensitivity analysis were initially planned.
The first was conducted with a leave-one-out approach
for the analyses including at least four studies. The
second was planned by excluding the studies with a
moderate and high risk of bias with the condition that at
least four studies could be included. A third sensitivity
analysis was added after the selection of findings. A
three-arm RCT randomized patients to receive pre-
operative levosimendan alone vs the combination of
levosimendan and intra-aortic balloon pump (IABP) vs
IABP alone. The results from the first two arms were
collected and included in this third sensitivity analysis
because the only difference between such arms was the
use of levosimendan [17].
Statistical analysis
Analyses were conducted only for outcomes reported in
a minimum of three studies. The Mantel-Haenszel
method was used to analyze dichotomous outcomes,
and results are reported as ORs with 95% CIs and two-
tailed p values. Continuous outcome differences were
analyzed using an inverse variance model with a 95% CI,
and values are reported as standard mean difference
(SMD). The p values were two-tailed. In both cases, p
values were considered significant if < 0.05. The presence
of statistical heterogeneity was assessed using the
Cochran Q test. Heterogeneity was likely if Q > df sug-
gested and was confirmed if p ≤ 0.10. Quantification of
heterogeneity was performed, and I2 values ranging from
0 to 24.9%, 25% to 49.9%, 50% to 74.9%, and > 75% were
considered as none, low, moderate, and high heterogen-
eity, respectively. If heterogeneity was quantified as low
or above, a random effects model was also used for sen-
sitivity analyses [18].
Results
Our systematic search identified a total of 601 findings
via an NHS Library Evidence search. No other findings
were retrieved manually. After removal of duplicates,
423 findings were screened and 171 were excluded be-
cause they were not focused on the topic of interest. As
shown in the PRISMA flow diagram in Additional file 2,
after the evaluation of the remaining 252 findings, only
6 RCTs were judged to be of interest for our quantitative
analyses: 5 RCTs included only patients with preopera-
tive severely depressed LVEF [13, 19–22], and 1 RCT in-
cluded both patients with preoperative severely
depressed LVEF and patients with intra-/postoperative
LCOS [14]. No study was focused only on patients with
intra-/postoperative LCOS. A list of the RCTs excluded
despite enrolling patients with severely depressed LVEF
(i.e., control subjects receiving milrinone or dobutamine)
is provided separately (Additional file 3). Overall, data
for up to 1728 patients were available, and data for up to
1224 patients were available for the subgroup of patients
with preoperative severely reduced LVEF. Table 2 shows
the characteristics of these studies, also including the
timing of drug administration. Table 3 summarizes the
results of primary and secondary outcome analyses.
Primary outcomes
In six studies [13, 14, 19–22], both mortality and need for
RRT were reported and were included in the primary
outcome analysis. Mortality was similar overall (OR 0.64
[0.37, 1.11], p = 0.11, I2 = 42%), but in the subgroup of
patients with low LVEF, levosimendan showed a
significantly lower mortality (OR 0.51 [0.32, 0.82], p =
0.005, I2 = 0%) (Fig. 1). Need for RRT was significantly
lower in the levosimendan group both overall (OR
0.63 [0.42, 0.94], p = 0.02, I2 = 0%) and in the
subgroup of patients with low LVEF (OR 0.55 [0.31,
0.97], p = 0.04, I2 = 0%) (Fig. 2).
Secondary outcomes
Researchers in five studies reported the incidence of
postoperative AF and supraventricular arrhythmias,
using different criteria (with a time frame of assessment
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Table 3 Summary of main results of primary and secondary outcomes
Heterogeneity
Outcome analyzed Studies Patients OR or SMD (95% CI) p Value I2 Statistic p Value
Mortality overall 6 1728 OR 0.64 (0.37, 1.11) 0.11 42% 0.12
Mortality in low LVEF 5 1224 OR 0.51 (0.32, 0.82) 0.005 0% 0.66
Need for RRT overall 6 1728 OR 0.63 (0.42, 0.94) 0.02 0% 0.91
Need for RRT in low LVEF 5 1224 OR 0.55 (0.31, 0.97) 0.04 0% 0.90
AF and SVT overall 5 1695 OR 0.62 (0.32, 1.18) 0.15 79% 0.0007
AF and SVT in low LVEF 4 1141 OR 0.52 (0.19, 1.40) 0.20 84% 0.0003
Myocardial damage overall 4 1645 OR 0.89 (0.52, 1.53) 0.68 29% 0.24
Myocardial damage in low LVEF 3 1141 OR 0.60 (0.15, 2.41) 0.47 53% 0.12
Mechanical support overall 6 1728 OR 0.38 (0.13, 1.10) 0.07 82% <0.0001
Mechanical support in low LVEF 5 1224 OR 0.29 (0.09, 1.00) 0.05 85% <0.0001
Hypotension overall 5 1695 OR 1.41 (0.92, 2.18) 0.12 0% 0.54
Hypotension in low LVEF 4 1191 OR 1.31 (0.82, 2.08) 0.26 0% 0.52
LCOS in low LVEF 4 1191 OR 0.55 (0.38, 0.79) 0.001 9% 0.35
AKI (risk, injury, failure of
RIFLE criteria)
3 817 OR 0.64 (0.44, 0.94) 0.02 9% 0.33
Duration of MV overall 3 567 SMD −0.11 (−0.28, 0.05) 0.18 0% 0.61
ICU LOS overall 4 1419 SMD −0.41 (−0.83, 0.02) 0.06 89% <0.0001
ICU LOS in low LVEF 3 962 SMD −0.78 (−1.90, 0.34) 0.17 92% <0.0001
Hospital LOS overall 3 567 SMD −0.73 (−1.89, 0.43) 0.22 93% <0.0001
Abbreviations: AF Atrial fibrillation, AKI Acute kidney injury, ICU Intensive care unit, LCOS Low cardiac output syndrome, LOS Length of stay, LVEF Left ventricular
ejection fraction, MV Mechanical ventilation, PICOS Population, intervention, comparison, outcomes, and study design, RIFLE Risk, injury, failure; loss, end-stage
renal disease, RRT Renal replacement therapy, SMD Standard mean difference, SVT Supraventricular tachycardia
Results are presented as OR or SMD, as appropriate, with 95% CI. Results presented in bold are statistically significant or with a trend toward statistically significant result
Table 2 Population included in studies selected for meta-analysis
Author, study [reference] Patients (n) and operations LVEF cutoffs Administration timing and dosages
Low LVEF only
Erb et al., 2014 [19] 33 On-pump CABG (with or without
valve)
<30% Before incision 12.5-mg total dose at 0.1 μg∙kg−1∙minute−1
Levin et al., 2012 [20] 252 On-pump CABG only <25% Preoperative 10-μg/kg bolus; 0.1 μg∙kg−1∙minute−1 for 23 h
Mehta et al., 2017 [13] 849 On-pump cardiac surgery <35% Before incision 0.2 μg/kg/minute for 1 h; 0.1 μg∙kg−1∙minute−1
for 23 h
Shah et al., 2014 [21] 50 Off-pump CABG only <30% Preoperative 0.133 μg∙kg−1∙minute−1 for 24 h
Sharma et al., 2014 [22] 40 CABG and mitral valve repair <30% Preoperative 200 μg∙kg−1 for 24 h
Lomivorotov et al., 2012a [17] 60 On-pump CABG only <35% Before incision 12-μg∙kg−1 bolus; 0.1 μg∙kg−1∙minute−1
for 24 h
LCOS only
– – – –
Low LVEF and LCOS
Landoni et al., 2017 [14] 504 All cardiac surgery <25%/or
LCOSb
Mainly postoperativeb 0.05 μg∙kg−1∙minute−1 for 48 h or until
ICU discharge
Abbreviations: CABG Coronary artery bypass grafting, LCOS Low cardiac output syndrome, LVEF Left ventricular ejection fraction
The studies are classified according to the subgroup of low LVEF and/or LCOS. We also report the number of patients in each study, the timing of levosimendan
(placebo) administration, and the outcomes of interest of our meta-analysis reported by each study
aThe study of Lomivorotov et al. [17] was a three-arm study with patients with low LVEF receiving preoperative levosimendan and intra-aortic balloon pump (IABP)
vs levosimendan alone vs IABP alone. The data from the first two groups were included in a sensitivity analysis
bIn this trial, only 4% of patients were randomized according to a preoperative low LVEF, 19% according to the need for IABP, 12% for difficult weaning from
cardiopulmonary bypass, and 65% for postoperative LCOS
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Fig. 1 Forest plot depicting analysis of the risk of mortality at longest follow-up in patients treated with levosimendan vs placebo. LVEF Left
ventricular ejection fraction, LCOS Low cardiac output syndrome, M-H Mantel-Haenszel
Fig. 2 Forest plot depicting analysis of the risk for postoperative renal replacement therapy in patients treated with levosimendan vs placebo.
LVEF Left ventricular ejection fraction, LCOS Low cardiac output syndrome, M-H Mantel-Haenszel
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not always reported) [13, 14, 20–22]. There was no differ-
ence in the incidence of postoperative AF and supraven-
tricular arrhythmias between levosimendan and placebo,
either overall (OR 0.62 [0.32, 1.18], p = 0.15, I2 = 79%) or
in the subgroup with low LVEF (OR 0.52 [0.19, 1.04], p =
0.20, I2 = 84%).
Researchers in four studies reported the incidence of
postoperative myocardial damage, using different criteria
and time frames of assessment [13, 14, 20, 22]. There
was no difference in the incidence of postoperative
myocardial damage between levosimendan and pla-
cebo, either overall (OR 0.89 [0.52, 1.53], p = 0.68,
I2 = 29%) or in the subgroup with low LVEF (OR
0.60 [0.15, 2.41], p = 0.47, I2 = 53%).
Researchers in six studies reported the need for postop-
erative cardiac mechanical support [13, 14, 19–22]. There
was a trend toward a lower incidence of support with
levosimendan, both overall (OR 0.38 [0.13, 1.10], p = 0.07,
I2 = 82%) and in the subgroup with low LVEF (OR 0.29
[0.09, 1.00], p = 0.05, I2 = 85%).
The incidence of hypotension during drug infusion was
reported in five studies [13, 14, 20–22]. There was no dif-
ference in the incidence of hypotension both overall (OR
1.41 [0.92, 2.18], p = 0.12, I2 = 0%) and in the subgroup
with low LVEF (OR 1.31 [0.82, 2.08], p = 0.26, I2 = 0%).
Researchers in only three studies reported some data
on AKI. In particular, Landoni et al. [14] reported the in-
cidence of risk, injury, and failure according to the RI-
FLE classification, whereas investigators in other two
studies [20, 21] reported the number of patients devel-
oping a serum creatinine increase at least > 50% from
baseline (with or without oliguria), separating them from
those requiring RRT. Such criteria equal at least the
“risk” stage of the RIFLE classification. On the basis of
pooling the results of these studies, levosimendan
significantly reduced the risk of AKI compared with
placebo (OR 0.64 [0.44, 0.94], p = 0.02, I2 = 9%). Re-
searchers in only three studies reported the duration of
MV [14, 19], and they found no difference between levo-
simendan and placebo, either overall (SMD −0.11
[−0.28, 0.05], p = 0.18, I2 = 0) or in the subgroup with
low LVEF (SMD −0.19 [−0.66, 0.27], p = 0.41, I2 = 0).
The ICU LOS was reported by investigators in four
studies [13, 14, 19, 22]. There was a trend toward a
shorter overall ICU stay in the levosimendan group
(SMD −0.41 [−0.83, 0.02], p = 0.06, I2 = 89%), but not
when the subgroup with low LVEF only was analyzed
(SMD −0.78 [−1.90, 0.34], p = 0.17, I2 = 92%) The
hospital LOS was reported by researchers in three
studies [14, 19, 22], and there were no differences be-
tween levosimendan and placebo (SMD −0.73 [−1.89,
0.43], p = 0.22, I2 = 93%). Finally, researchers in four
studies of the subgroup of RCTs including only pa-
tients with preoperative low LVEF reported the inci-
dence of postoperative LCOS [13, 20, 21]. There was
a significantly lower incidence of LCOS in patients
treated with levosimendan (OR 0.55 [0.38, 0.79], p =
0.001, I2 = 9%) (Fig. 3).
Risk of bias assessment and sensitivity analyses
The two recent RCTs [13, 14] and one study were scored as
having a low risk of bias [22], whereas the other three stud-
ies had at least a moderate risk of bias [19–21]. Because half
of the RCTs were scored with at least moderate risk of bias,
Fig. 3 Forest plot depicting analysis of the risk for postoperative low cardiac output syndrome in patients treated with levosimendan vs placebo
and with low preoperative left ventricular ejection fraction. M-H Mantel-Haenszel
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the sensitivity analysis including only RCTs at low risk
(three studies) was not conducted [19–22]. The funnel plots
of the two primary outcomes suggest no significant risk of
publication bias.
We performed a series of sensitivity analyses with the
leave-one-out approach for all the analyses including a
minimum of four studies (thus remaining with at least
three studies). With regard to mortality, the only change
was the nonsignificant reduction in mortality with levo-
simendan in the subgroup with low LVEF only when
removing the study by Levin et al. [20] (changed to p =
0.05). No other changes were seen by taking out any of
the other five studies individually.
For postoperative RRT, exclusion of either the study
by Mehta et al. [13] or the one by Levin et al. [20] dem-
onstrated a trend toward overall lower need for RRT in
the levosimendan group (p = 0.07 and p = 0.06, respect-
ively). Moreover, in the subgroup with low LVEF only,
exclusion of one of these studies [13, 20] made the
difference between groups nonsignificant (p = 0.13 and
p = 0.11, respectively). No changes were found after
removal of any of the other four studies. Details of sensi-
tivity analyses for secondary outcomes are provided
separately (Additional file 4).
The third sensitivity analysis was conducted by adding
the results of the study of Lomivorotov et al. [17], in
which the authors randomized patients with preopera-
tive ejection fraction < 35% to three arms: preoperative
levosimendan alone vs combination of levosimendan
and IABP vs IABP alone. The results from the first two
arms were collected. This study provided data on most
of the outcomes of interest of our meta-analysis, and its
inclusion did not change any of the results for primary
and secondary outcomes.
Discussion
We conducted the present meta-analysis because of the
discordance between the results of two recent large
RCTs investigating the use of levosimendan in high-risk
patients undergoing cardiac surgery [13, 14] and the re-
sults of previously published meta-analyses [11, 12]. The
two recent RCTs failed to show a beneficial effect of
levosimendan compared with placebo [13, 14], whereas
the two meta-analyses had opposite results [11, 12]. An-
other reason for conducting our study was the evidence
in one RCT of a beneficial effect of levosimendan in the
subgroup of patients with more severe reduction of
LVEF (<25%) and in those undergoing isolated coronary
artery bypass grafting (CABG); moreover, such RCTs
showed a trend toward lower mortality at 90 days for
levosimendan (4.7% vs placebo 7.1%, p = 0.12) [13].
Although the two recent RCTs included a broader
spectrum of cardiac surgical interventions and were
not focused exclusively on patients undergoing CABG
[13, 14], previous studies were focused mostly on pa-
tients with coronary artery disease undergoing CABG
(isolated [20, 21] or CABG with or without valve
surgery [19, 22]). Moreover, such studies have used a
more restrictive cutoff for preoperative LVEF (<25%
[20] or < 30% [19, 21, 22]).
The primary endpoint of our meta-analysis was the
difference in mortality and need for postoperative RRT
in high-risk patients undergoing cardiac surgery receiv-
ing levosimendan compared with placebo. We therefore
excluded studies comparing levosimendan with other
pharmacological strategies, such as dobutamine and
milrinone. We found only six RCTs comprising over
1700 patients, 1200 of whom over belonged to the sub-
group of patients with preoperative severely reduced
LVEF only (<35%). We investigated mortality and the
need for postoperative RRT as primary outcomes.
Whereas overall mortality was not different, levosimen-
dan compared with placebo significantly reduced mortal-
ity in the subgroup of patients with preoperative severely
reduced LVEF. Moreover, levosimendan significantly
decreased the need for postoperative RRT after cardiac
surgery, both overall and in the subgroup of patients
with preoperative severely reduced LVEF (<35%).
These findings are not surprising, because even the
larger RCT [13] showed a trend toward beneficial effects
of levosimendan in patients with more depressed LVEF
(<25%) and also among those with more advanced
chronic kidney disease (estimated glomerular filtration
rate < 60 ml/minute). Several aspects, however, should
be taken into account. Levosimendan is a calcium-
sensitizing inotrope as well as a KATP opener, and it has
organ-protective properties. The opening of KATP chan-
nels located in the plasma membrane of vascular smooth
muscle cells and at the level of mitochondria improves
energy homeostasis, protecting the heart from calcium
overload and oxidative injury [23, 24] and optimizing
mitochondrial energy balance [24]. At coronary artery
levels, levosimendan produces vasodilation through the
increase in extracellular potassium, resulting in an in-
crease in blood flow to ischemic myocardial regions
[25]. This ultimately results in improved myocardial
function, as shown by enhanced arterial-ventricular
coupling [26]. For such reasons, patients with coronary
artery disease undergoing CABG may experience a
greater benefit from levosimendan by additive protection
in areas at high risk of perioperative myocardial injury.
Therefore, it is likely that our results differ from those of
the recent RCTs, because our meta-analysis also in-
cluded four studies that randomized only patients under-
going CABG (with or without valve surgery). A favorable
effect of levosimendan might have been blunted in the
larger RCTs that included a wider spectrum of patients
undergoing cardiac surgery.
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The advantageous renal effects of levosimendan are
reinforced by a lower number of patients with postoper-
ative AKI according to the RIFLE criteria. We believe
that such results can be attributed primarily to an im-
provement in systemic hemodynamics. The increase in
cardiac output and the reduction in right-sided pres-
sures, including central venous pressure [27], may de-
crease renal vein pressure. Such effects may increase
renal flow per se. Additionally, because renal blood flow
depends on vascular resistance, the local vasodilation
obtained by levosimendan through the KATP channels in
the afferent arterioles increases renal perfusion, thus in-
creasing glomerular filtration pressure and filtration rate.
Such effects on renal arterioles are different from those
of other inotropes/vasoconstrictor agents. Also, nonhe-
modynamic effects such as preconditioning, anti-
inflammatory effects, and antiapoptotic properties may
have played a role in improving renal function [28].
The preoperative use of levosimendan has also been
studied in CABG patients with preserved LVEF, and, al-
though a reduction in myocardial injury and an increase
in cardiac index in the levosimendan group were shown,
the study failed to show a clear benefit of this strategy
[29]. In the studies included in our meta-analysis, levosi-
mendan has been used with varying timing of adminis-
tration. In three studies, levosimendan has been given
preoperatively 24 h before surgery [20–22], whereas re-
searchers in two studies initiated drug administration
just before surgery [13, 19], and another study included
mainly patients after difficult weaning from CPB or pa-
tients who developed profound cardiovascular dysfunc-
tion in the ICU [14].
It is interesting to note that levosimendan was associ-
ated with a lower incidence of LCOS in the subgroup of
patients with low LVEF only and with a trend toward
lower use of mechanical circulatory support, both overall
and in the subgroup of patients with low LVEF only. In
our study, we did not perform a comparison between
levosimendan and other inotropes. Levosimendan has a
mechanism different from that of other inotropes, which
typically increase intracellular calcium levels with subse-
quent higher myocardial oxygen demand, adverse effects
[30], and higher mortality [31, 32]. The rise of intracellu-
lar calcium levels does not happen with levosimendan,
and therefore the drug does not increase in myocardial
oxygen consumption [33].
One of the main issues with the use of levosimendan
is related to its pharmacological properties. Beneficial is-
chemic myocardial preconditioning may be obtained if
administration of the drug is performed several hours
before the insult [9], but, as reported above, researchers
in only three studies admitted patients to the ICU 24 h
before surgery in order to start the drug infusion
[20–22]. In two other studies, investigators started the
administration of levosimendan after anesthesia induc-
tion without a bolus [13, 19], and in one study, re-
searchers used levosimendan mainly for difficult
weaning from CPB or for postoperative LCOS [14]. It
should be noted that when levosimendan is used at the
beginning of surgery, it may be useful to administer a drug
bolus to reach a peak concentration that is then main-
tained by infusion [9]. Therefore, in these studies, the
beneficial effects of levosimendan may have been reduced
by the late administration, the absence of a bolus, and
possibly a dilution through the CPB circuit. It should be
noted that bolus administration increases the risk of
hypotension requiring the administration of noradren-
aline, especially when given in a high dose (24 μg/kg) [34];
however, the experts of the European consensus on the
use of perioperative levosimendan do not recommend a
bolus, and in cases where a bolus is administered, they
mostly suggest lower dosages (6 μg/kg, 67%; 12 μg/kg,
29%; 24 μg/kg, 4%) [9].
Another fundamental aspect in the cardiac surgery pa-
tient is the presence of diastolic dysfunction associated
with depression of contractility. In these cases, levosi-
mendan has shown improvements [35] or neutral effects
on diastolic function [36], which instead is worsened by
the use of catecholamines [30] and unchanged by inhibi-
tors of phosphodiesterase [37, 38]. A large number of
patients undergoing cardiac surgery are currently treated
with beta-blockers, and levosimendan can offer advan-
tages because it does not interfere with the receptor-
mediated mechanisms of catecholamines and does not
impair left ventricular diastolic function [39, 40]. Most
of the patients with heart failure and/or severe systolic
dysfunction are treated with beta-blockers [41, 42]. It is
worth noting that, apart from two small studies (Shah et
al. [21] and Sharma et al. [22], where a minority of pa-
tients were receiving beta-blockade therapy [14% and
12.5%, respectively]), most of the patients in the other
studies of our meta-analysis were treated with beta-
blockade therapy (Mehta et al. [13], ~ 80%; Landoni
et al., [14], > 60%; Levin et al. [20], ~ 85%; Erb et al. [19],
> 90%). Whether patients with preoperative treatment
with beta-blockers may benefit more from levosimendan
remains speculative and should be explored in subgroup
analyses. Furthermore, levosimendan could offer advan-
tages in patients with right ventricular systolic and dia-
stolic dysfunction, with or without associated pulmonary
hypertension [43–45].
Limitations
Our results should be interpreted cautiously because we
found a reduced number of studies, and three of them
[19–21] had moderate risk of bias. Moreover, we de-
scribe the clinical heterogeneity of the included studies
with regard to the timing of levosimendan
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administration and the surgical population. Three stud-
ies administered levosimendan 24 h before surgery [20–
22], but this may not always be feasible, especially in pa-
tients with urgent need for surgery.
Our results partially contradict those of the two recent
RCTs [13, 14], but it should be kept in mind that such
studies also have several limitations. In the CHEETAH trial
[14], most of the patients (96%) received levosimendan
after CPB or postoperatively for profound cardiovascular
dysfunction (LCOS). On one hand, a low-dose infusion of
levosimendan was used, which was possibly explained by
severe clinical conditions (hypotension and/or high doses
of vasoactive drugs), but on the other hand, such a dose
may not allow full achievement of the intended pharmaco-
logical effect. There was almost 13% mortality in both
groups, and this was almost double the mortality expected
by the initial sample size calculation. This mortality could
be explained by the high doses of inotropes, which are in-
dependently associated with mortality in cardiac surgery
[31, 32]. The other recent LEVO-CTS study [13] was a
phase III trial designed for Food and Drug Administration
approval of levosimendan. It was a well-designed RCT with
contributions from European colleagues with a high level
of experience and involved 70 centers over 26 months.
Thus, on average, there was not a large use of the drug per
center, introducing a potential bias in the results. Nonethe-
less, the same study showed a trend toward lower mortality
at 90 days for levosimendan (p = 0.12).
Conclusions
Levosimendan reduces mortality in patients with pre-
operative severely reduced ejection fraction (<35%).
Moreover, levosimendan significantly reduces the need
for RRT after high-risk cardiac surgery.
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